Painful Diabetic Neuropathy: How the AAN Graded the Evidence

When the American Academy of Neurology updated its guideline on oral and topical treatment of painful diabetic polyneuropathy in 2022, it reached a conclusion that unsettles the search for a single best drug. Tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentinoids, and sodium-channel blockers all reduce pain, and their effect sizes are broadly comparable. Rather than name one first-line agent, the guideline (Price and colleagues, Neurology, January 2022) recommends offering a medication from any of these classes, switching to a different class when one fails, and not using opioids. That framing is a lesson in how to read comparable-efficacy evidence.

What the guideline actually graded

The AAN did not simply list drugs. It pooled trials by mechanism and estimated a standardized mean difference (SMD) for each class, a way of putting different pain scales on one ruler. Gabapentinoids landed at an SMD of about 0.44, SNRIs at 0.47, and sodium-channel blockers at 0.56, with overlapping confidence intervals that cluster near a medium effect. Tricyclics showed the largest point estimate, roughly 0.95, but the guideline explicitly tempered that number with low confidence in the estimate, because the underlying trials were older, smaller, and more heterogeneous.

This is the crux of evidence grading. A larger number on the page does not automatically mean a stronger recommendation. The AAN separates the size of an effect from the certainty that the effect is real and reproducible. A moderate effect measured precisely can carry a firmer recommendation than a large effect measured loosely. When the confidence intervals for several classes overlap, the honest reading is that no class has been shown to be reliably better than the others.

From effect sizes to recommendations

The practical recommendations follow from that reading. The guideline advises clinicians to counsel patients on the expected magnitude of benefit, which is real but partial, and to offer a trial of a tricyclic, an SNRI, a gabapentinoid, or a sodium-channel blocker. Each of these carries a Level B recommendation, the AAN's language for a course of action that should generally be followed based on the strength of evidence behind it.

Two further points give the guideline its shape. First, because efficacy is comparable across classes, the choice among them turns on factors other than raw effect size: side-effect profiles, other medical conditions, drug interactions, cost, and patient preference. Second, if one medication does not work or causes intolerable side effects, the guideline recommends trying a drug from a different class rather than another drug within the same class. The logic is that switching mechanisms is more likely to help than swapping one gabapentinoid for another.

The recommendation against opioids also carries a Level B designation. The guideline concludes that opioids should not be used for painful diabetic neuropathy, reflecting weak evidence of durable benefit alongside well-documented harms. That is a case where evidence grading points not toward a preferred drug but away from a whole category.

What OPTION-DM adds

A guideline synthesizes what already exists; it cannot test head-to-head comparisons that were never run. That gap is exactly what the OPTION-DM trial, published in The Lancet in 2022 by Tesfaye and colleagues, set out to fill. It was a multicenter, double-blind, randomized crossover study across 13 UK centers, and it compared three treatment pathways: amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin.

The result reinforced the guideline's central theme. Average pain scores fell from a mean of about 6.6 at baseline to roughly 3.3 at week 16, and the three pathways produced no significant difference between them in the primary outcome. In other words, a tricyclic-first, a gabapentinoid-first, and an SNRI-first strategy landed in the same place. What differed were the side effects, not the pain relief: dry mouth was more common on the amitriptyline pathway, dizziness on the pregabalin pathway, and nausea on the duloxetine pathway. That pattern is precisely why the guideline says to let tolerability and patient factors, rather than a presumed efficacy ranking, drive the choice.

OPTION-DM added one more finding the guideline could only gesture toward. For patients whose pain was not adequately controlled on a single drug, adding a second agent produced a further meaningful reduction in pain compared with staying on monotherapy. Combination therapy was reasonably tolerated and helped the subgroup with a suboptimal monotherapy response. That is a genuinely useful piece of evidence for a common clinical situation, and it slots neatly into the AAN's stepwise framing.

Reading comparable-efficacy evidence

The recurring temptation with a table of drugs is to rank them and stop reading. The AAN guideline and OPTION-DM together push against that instinct. When several options produce similar benefit within the noise of the data, the useful questions shift. Which side effects can this particular person tolerate? What else are they taking? What did the trials actually measure, and how confident are we in each estimate? A finding of comparable efficacy is not a failure to find a winner. It is information that widens the set of reasonable first choices and moves the decision toward the individual in front of the clinician.

It also guards against a subtle error: treating the largest point estimate as the safest bet. The tricyclic result is a good example, impressive on paper yet flagged for low confidence. Grading systems exist so that certainty and magnitude are weighed separately rather than collapsed into a single ranking. Both the AAN guideline and OPTION-DM address exactly this kind of uncertainty, and both point to the same disciplined conclusion.

This article is educational and is not medical advice; decisions about treatment for diabetic neuropathy should be made with a qualified clinician who knows the individual case.